JP3152467B2 - Oral composition - Google Patents
Oral compositionInfo
- Publication number
- JP3152467B2 JP3152467B2 JP32030591A JP32030591A JP3152467B2 JP 3152467 B2 JP3152467 B2 JP 3152467B2 JP 32030591 A JP32030591 A JP 32030591A JP 32030591 A JP32030591 A JP 32030591A JP 3152467 B2 JP3152467 B2 JP 3152467B2
- Authority
- JP
- Japan
- Prior art keywords
- dentin
- aluminum
- sodium
- fluoride
- oral composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 23
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 claims description 13
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 11
- 229910052782 aluminium Inorganic materials 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000004268 dentin Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- -1 aluminum compound Chemical class 0.000 description 8
- 201000009241 dentin caries Diseases 0.000 description 8
- 201000002170 dentin sensitivity Diseases 0.000 description 8
- 229940091249 fluoride supplement Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 208000002925 dental caries Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 210000003298 dental enamel Anatomy 0.000 description 4
- 239000000551 dentifrice Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940034610 toothpaste Drugs 0.000 description 4
- 239000000606 toothpaste Substances 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000002344 surface layer Substances 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WJQZZLQMLJPKQH-UHFFFAOYSA-N 2,4-dichloro-6-methylphenol Chemical compound CC1=CC(Cl)=CC(Cl)=C1O WJQZZLQMLJPKQH-UHFFFAOYSA-N 0.000 description 2
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- ICPMTQOYWXXMIG-OPDGVEILSA-K aluminum;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Al+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O ICPMTQOYWXXMIG-OPDGVEILSA-K 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 208000005358 Tooth Attrition Diseases 0.000 description 1
- 208000004188 Tooth Wear Diseases 0.000 description 1
- MEYPRMGRFQCXHY-UHFFFAOYSA-N [Na].F[Si](F)(F)F Chemical compound [Na].F[Si](F)(F)F MEYPRMGRFQCXHY-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-N fluorophosphoric acid Chemical compound OP(O)(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- AMCPECLBZPXAPB-UHFFFAOYSA-N propane-1,2,3-triol;sodium Chemical compound [Na].OCC(O)CO AMCPECLBZPXAPB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- CKVCFYYFFUHCDP-UHFFFAOYSA-M sodium;phosphoric acid;fluoride Chemical compound [F-].[Na+].OP(O)(O)=O CKVCFYYFFUHCDP-UHFFFAOYSA-M 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- RXSHXLOMRZJCLB-UHFFFAOYSA-L strontium;diacetate Chemical compound [Sr+2].CC([O-])=O.CC([O-])=O RXSHXLOMRZJCLB-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- 210000004746 tooth root Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は象牙質知覚過敏症の予防
および治療に優れた効果を有し、安定で良好な使用感を
有する口腔用組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an oral composition having an excellent effect on the prevention and treatment of dentin hypersensitivity, and having a stable and good feeling of use.
【0002】[0002]
【従来の技術および課題】象牙質知覚過敏症とは、う蝕
や歯の咬耗、摩耗および歯肉の退縮などの原因により歯
のエナメル質またはセメント質が消失し、象牙質が露出
するため、外来的な刺激に対して過敏となる症状をい
い、刺激によって引き起こされる痛みは日常の食生活に
かなりの支障をきたすものである。このため、従来より
象牙質知覚過敏症の予防および治療に関しては数多くの
提案がなされている。例えば、象牙質知覚過敏症に有効
な薬剤として、ホルムアルデヒド、フッ化物、塩化亜
鉛、硝酸銀、硝酸カリウム、くえん酸塩、ストロンチウ
ム塩(歯医学誌:3,116−149,1984、J.Pe
riodontol.:10,351−363,1983)、乳酸ア
ルミニウム等(特開昭61−36212、特開昭61−
155312)が提案されている。また、硝酸カリウム
とフッ素、酢酸ストロンチウムとフッ素等(特開平3−
7215)の組み合わせによる口腔組成物も開示されて
いる。しかしながら、これら薬剤は十分に有効な象牙質
知覚過敏抑制効果および優れた使用感を有さず、かかる
欠点のない口腔組成物の出現が望まれていた。さらに
は、象牙質の露出により、歯根面および象牙質う蝕の発
生頻度が高くなるにもかかわらず、かかる歯根面および
象牙質う蝕抑制作用を有する口腔組成物についての提案
もなされていない。2. Description of the Related Art Dentin hypersensitivity refers to dentin being exposed due to loss of tooth enamel or cementum due to caries, tooth attrition, wear and gingival regression. Symptoms that become hypersensitive to extraneous stimuli, and the pain caused by the stimuli is a significant obstacle to daily eating habits. For this reason, many proposals have been made for the prevention and treatment of dentin hypersensitivity. For example, effective drugs for dentin hypersensitivity include formaldehyde, fluoride, zinc chloride, silver nitrate, potassium nitrate, citrate, and strontium salts (Dental Medicine Journal: 3,116-149, 1984, J. Pe).
riodontol .: 10,351-363, 1983), aluminum lactate, etc. (JP-A-61-36212, JP-A-61-36212).
155312) has been proposed. Further, potassium nitrate and fluorine, strontium acetate and fluorine, etc.
7215) is also disclosed. However, these drugs do not have a sufficiently effective dentin hypersensitivity inhibitory effect and an excellent feeling in use, and it has been desired to develop an oral composition free of such defects. Furthermore, despite the fact that the frequency of occurrence of root surfaces and dentin caries increases due to exposure of dentin, no oral composition having such a root surface and dentin caries inhibiting action has been proposed.
【0003】[0003]
【課題を解決するための手段】そこで本発明者らは、優
れた象牙質知覚過敏抑制作用および使用感を有する口腔
組成物を得るべく鋭意研究した結果、ある種の薬剤を、
一定濃度かつ一定配合比で組み合わせることによって、
相乗的な象牙質知覚過敏抑制効果および優れた使用感を
有するのみならず、歯根面および象牙質う蝕抑制作用を
も有する口腔用組成物が得られることを見いだし、本発
明を完成するに至った。すなわち、本発明は水溶性アル
ミニウム化合物およびフッ化物を含有する口腔用組成物
であって、フッ素濃度が100〜2000ppmであり、
フッ素とアルミニウムの配合比率がモル比がF:Al=
1:0.3〜1:3であり、pHが5〜10であることを
特徴とする口腔用組成物を提供するものである。Means for Solving the Problems Accordingly, the present inventors have conducted intensive studies to obtain an oral composition having an excellent dentin hypersensitivity inhibitory action and a feeling of use.
By combining at a certain concentration and a certain mixing ratio,
The present inventors have found that an oral composition having not only a synergistic effect of suppressing dentin hypersensitivity and an excellent feeling in use but also an effect of suppressing the root surface and dentin caries can be obtained. Was. That is, the present invention is an oral composition containing a water-soluble aluminum compound and a fluoride, and has a fluorine concentration of 100 to 2000 ppm,
The molar ratio of fluorine and aluminum is F: Al =
The present invention provides an oral composition characterized by having a pH of from 1: 0.3 to 1: 3 and a pH of from 5 to 10.
【0004】本発明に用いる水溶性アルミニウム化合物
は、水溶性であれば特に限定されないが、乳酸アルミニ
ウム、グルコン酸アルミニウム、酒石酸アルミニウム、
クエン酸アルミニウム等のカルボン酸化合物および塩化
アルミニウム、アルミニウムアラントイン等を使用する
ことができる。一般に、乳酸アルミニウム、アルミニウ
ムアラントイン等が好ましい。The water-soluble aluminum compound used in the present invention is not particularly limited as long as it is water-soluble, but aluminum lactate, aluminum gluconate, aluminum tartrate,
Carboxylic acid compounds such as aluminum citrate and the like, aluminum chloride, aluminum allantoin and the like can be used. Generally, aluminum lactate, aluminum allantoin and the like are preferred.
【0005】フッ化物としては、モノフルオルリン酸
塩、フッ化スズ、フッ化ナトリウム、フッ化珪素ナトリ
ウム、フッ化アンモニウム等を用いてもよく、好ましく
は、モノフルオルリン酸塩、フッ化ナトリウムである。
フッ化物は、フッ素濃度が100〜2000ppmとなる
ように組成物中に配合する。100ppm以下では所望の
効果が得られず、2000ppm以上では安全性が問題と
なるからである。一般に、800〜1600ppmである
ことが好ましい。As the fluoride, monofluorophosphate, tin fluoride, sodium fluoride, sodium silicon fluoride, ammonium fluoride and the like may be used. Sodium.
Fluoride is blended in the composition such that the fluorine concentration becomes 100 to 2000 ppm. If it is less than 100 ppm, the desired effect cannot be obtained, and if it is more than 2000 ppm, safety is a problem. Generally, it is preferably 800 to 1600 ppm.
【0006】本発明の口腔用組成物には、かかるフッ化
物と水溶性アルミニウム化合物を、フッ素およびアルミ
ニウムのモル比に換算して、F:Al=1:0.3〜
1:3の配合比率で配合する。フッ素に対するアルミニ
ウムの比率が0.3以下であると、歯根面および象牙質
う蝕抑制作用が低く、3以上となると使用感が悪いから
である。好ましくは、F:Al=1:1である。In the oral composition of the present invention, the fluoride and the water-soluble aluminum compound are converted to a molar ratio of fluorine and aluminum, whereby F: Al = 1: 0.3 to
It is blended at a blending ratio of 1: 3. When the ratio of aluminum to fluorine is 0.3 or less, the effect of suppressing the root surface and dentin caries is low, and when it is 3 or more, the feeling of use is poor. Preferably, F: Al = 1: 1.
【0007】本発明の口腔用組成物のpHは、pH5〜1
0、好ましくは5〜8である。pHが5以下であると、
使用感が悪く、pHが10以上であると刺激があるから
である。The pH of the oral composition of the present invention is pH 5-1.
0, preferably 5 to 8. When the pH is 5 or less,
This is because the feeling of use is poor and if the pH is 10 or more, there is irritation.
【0008】本発明の口腔用組成物は、常法により製造
することができ、歯磨(例えば、練歯磨、潤製歯磨、液
状歯磨、マウスウォッシュ等)、ペースト状組成物(例
えば、口腔用パスタ、歯肉マッサージクリーム等)、液
状口腔清涼剤等の形態にすることができる。さらに、前
記の成分に加え、組成物の形態に応じて通常の有効基材
を用いてもよい。例えば、潤滑剤として、ソルビトー
ル、グリセリン等を用いることができ、その配合量は組
成物全体に対して10〜60%、好ましくは20〜50
%である。さらには、界面活性剤、香料、粘結剤、甘味
剤等を配合することができる。[0008] The oral composition of the present invention can be produced by a conventional method, and includes dentifrice (eg, toothpaste, lubricating dentifrice, liquid dentifrice, mouthwash), and paste-like composition (eg, oral pasta). , Gum massage cream, etc.), liquid oral fresheners and the like. Further, in addition to the above-mentioned components, ordinary effective base materials may be used depending on the form of the composition. For example, sorbitol, glycerin and the like can be used as a lubricant, and the compounding amount thereof is 10 to 60%, preferably 20 to 50% based on the whole composition.
%. Furthermore, surfactants, flavors, binders, sweeteners and the like can be added.
【0009】[0009]
【実施例】次に実験例および実施例を挙げて本発明をさ
らに詳しく説明する。実験例においては、本発明の口腔
用組成物の有する象牙質知覚過敏抑制作用、歯根面およ
び象牙質う蝕抑制作用および使用感を評価した。 実験例1(象牙質知覚過敏抑制作用の評価) 歯の表層が急速に失われた場合、すなわち、エナメル質
やセメント質が急速に損耗して下在の象牙質面が露出し
た場合に、象牙質の知覚過敏が生じるといわれている。
象牙質には象牙細管とよばれる無数の細い空管があり、
象牙質が露出するとその象牙細管を通して物理化学的刺
激が歯髄に直達しやすくなり、一過性の疼痛用症状を生
じるといわれている。従って、露出した象牙細管を閉塞
することは知覚過敏を予防および治療するために重要な
ことである。そこで、Pashleyらの方法(J.Dent.Re
s.57,187−193,1987)を用いて、各種
薬剤による象牙細管の狭窄および閉塞の程度を評価し
た。Next, the present invention will be described in more detail with reference to experimental examples and examples. In the experimental examples, the effect of suppressing the hypersensitivity to dentin, the effect of suppressing the root surface and dentin caries, and the feeling of use of the oral composition of the present invention were evaluated. Experimental Example 1 (Evaluation of Dentin Hypersensitivity Inhibition) When the surface layer of the tooth was rapidly lost, that is, when the enamel and cementum were rapidly worn away and the underlying dentin surface was exposed, It is said that quality hyperesthesia occurs.
Dentin has countless thin empty tubes called dentin tubules,
It is said that when dentin is exposed, physicochemical stimuli easily reach the pulp through the dentin tubules, causing transient painful symptoms. Therefore, obstructing exposed dentin tubules is important for preventing and treating hyperesthesia. Therefore, the method of Pashley et al. (J. Dent.
s. 57, 187-193, 1987) were used to evaluate the degree of stenosis and occlusion of dentinal tubules by various drugs.
【0010】方法 牛の歯根からブロックを切出し、研磨を行って薄切片を
作製し試料とした。試料を固定し、表1に示した薬剤
に、室温で15分間浸漬処理し、処理前後で生理食塩水
を流し、試料を通過する単位時間当たりの生理食塩水の
量を測定した。ただし、薬剤は全てpH6.5に調整し
た。Method A block was cut out from the root of a cow and polished to produce a thin section, which was used as a sample. The sample was fixed, immersed in the medicine shown in Table 1 at room temperature for 15 minutes, physiological saline was flowed before and after the treatment, and the amount of physiological saline per unit time passing through the sample was measured. However, all drugs were adjusted to pH 6.5.
【数1】 (Equation 1)
【0011】[0011]
【表1】 薬剤名 アルミニウム量(%) フッ素量(ppm) 減少率(%) 乳酸アルミニウム 0.02 500 53 0.1 0 50 0.1 50 51 0.1 500 75 0.1 1000 95 0.2 1000 92 グルコン酸アルミニウム 0.1 0 43 0.1 500 70 0.1 1000 90 0.15 500 82 0.2 1000 85 酒石酸アルミニウム 0.1 0 31 0.1 500 78 0.1 1000 90 0.2 1000 88 くえん酸アルミニウム 0.03 1000 70 0.1 0 40 0.1 500 78 0.1 1000 92 0.2 1000 90 上記結果により、水溶性アルミニウム単独の場合に比べ
て、フッ化物を配合した場合に効果の向上がみられ、特
にF:Al=1:0.3〜1:3で、かつフッ化物濃度
が100〜2000ppmの範囲内にある時に著しい効果
が認められた。Table 1 Chemical name Aluminum content (%) Fluorine content (ppm) Reduction rate (%) Aluminum lactate 0.02 500 53 0.1 0 50 0.1 50 51 0.1 500 75 0.1 1000 95 95. 2 1000 92 Aluminum Gluconate 0.1 0.43 0.1 500 70 0.1 1000 90 0.15 500 82 0.2 1000 85 Aluminum Tartrate 0.1 0.31 0.1 500 78 0.1 1000 90 0.0 2 1000 88 Aluminum citrate 0.03 1000 70 0.1 0 40 0.1 500 78 0.1 1000 92 0.2 1000 90 According to the above results, fluoride was compounded compared to the case of water-soluble aluminum alone. In particular, the effect is improved, especially when F: Al = 1: 0.3 to 1: 3 and the fluoride concentration is in the range of 100 to 2000 ppm. Have effect was observed.
【0012】実験例2(根面および象牙質う蝕抑制作用
の評価) 象牙質はエナメル質より軟らかくかつ耐酸性が低いた
め、う蝕が発生しやすいことが知られている。そのため
知覚過敏をおこす露出した象牙質ではう蝕が発生しやす
い事が指摘されている。また近年、う蝕抑制効果は歯牙
を用いたin vitroによる再石灰化評価方法をもってその
効果が評価できることが認められている。この再石灰化
評価法とは、牛歯のエナメル質または象牙質切片に酸
(虫歯)と薬剤(歯磨剤等)の処理を行い、処理により
生じる歯牙のミネラル量の増減(増加を再石灰化、減少
を脱灰と称する)を測定することにより評価する方法で
ある。その方法を用いて象牙質う蝕抑制効果の評価を行
った。Experimental Example 2 (Evaluation of root surface and dentin caries inhibiting action) It is known that dentin is softer and lower in acid resistance than enamel, so that caries is easily generated. Therefore, it has been pointed out that cariousness is likely to occur in exposed dentin that causes hyperesthesia. In recent years, it has been recognized that the effect of inhibiting dental caries can be evaluated by an in vitro remineralization evaluation method using teeth. This remineralization evaluation method is to treat enamel or dentin sections of bovine teeth with acid (cavities) and drugs (dentifrice, etc.), and to increase or decrease (increase remineralization) the amount of minerals in the teeth caused by the treatment. , The decrease is referred to as demineralization). The dentin caries suppression effect was evaluated using the method.
【0013】方法 牛歯の歯根部象牙質をブロック状に切出し、アクリル樹
脂で包埋したのち歯牙の表層面を研磨した。研磨の後、
研磨表層を0.1M乳酸(pH4.5)をもちいて48時
間処理することにより人工的に脱灰層を作成した。脱灰
したブロックの表層の半分を水不溶性高分子溶液を用い
て被覆し、後記に示した薬液(1日2回)および人工唾
液への浸漬を交互に10日間行った。歯牙ブロックを厚
み100μmに切削研磨後、X線撮影したフィルムを画
像処理することにより、次式に基づいて再石灰化量を算
出した(J.M.Ten Cate,J.Dent Res.:69,6
14−619,1990,J.R.Mellberg,J.Dent.
Res.:65,959−962,1986)。Method The root dentin of bovine teeth was cut out in a block shape, embedded in acrylic resin, and then the surface of the tooth was polished. After polishing,
The polished surface layer was treated with 0.1 M lactic acid (pH 4.5) for 48 hours to artificially produce a decalcified layer. Half of the surface layer of the decalcified block was coated with a water-insoluble polymer solution, and immersed in a chemical solution (twice a day) and artificial saliva described later, alternately, for 10 days. After the tooth block was cut and polished to a thickness of 100 μm, the amount of remineralization was calculated based on the following equation by performing image processing on the X-rayed film (JM Ten Cate, J. Dent Res .: 69, 6
14-619, 1990, JR Mellberg, J. Dent.
Res .: 65, 959-962, 1986).
【数2】 (Equation 2)
【0014】[0014]
【表2】 薬 液 (w/w%) 乳酸アルミニウム MFP 再石灰化量(%) 0 0 3 1 0 4 0 0.35 20 1 0.35 32 1 0.7 74 上記試験結果により、乳酸アルミニウムのみでは、う蝕
に対する抑制効果がほとんどないのに対して、本発明の
乳酸アルミニウムとフッ化物を加えた薬液では強力なう
蝕抑制効果が得られることが分かった。Table 2 Chemical solution (w / w%) Aluminum lactate MFP Remineralization amount (%) 0 3 10 4 0 0.35 20 1 0.35 32 1 0.7 74 According to the above test results, aluminum lactate It was found that while only a caries solution had almost no caries suppressing effect, a strong caries suppressing effect was obtained with the chemical solution of the present invention to which aluminum lactate and fluoride were added.
【0015】実験例3(使用感の評価) 表3に示す処方の練歯磨を調製し、その使用感を専門パ
ネラー15名により官能評価した。 評価基準 ○:使用感に問題なし △:使用感に少し問題あり ×:使用感に問題ありExperimental Example 3 (Evaluation of feeling of use) Toothpaste having the formulation shown in Table 3 was prepared, and the feeling of use was organoleptically evaluated by 15 expert panelists. Evaluation criteria ○: There is no problem in usability △: There is some problem in usability ×: There is a problem in usability
【0016】[0016]
【表3】 原料名 配合量(%) A B C D E F G H シリカ 20 20 20 20 20 20 20 20 カルボキシメチル 2 2 2 2 2 2 2 2 セルロースナトリウム ラウリル硫酸ナトリウム 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 サッカリンナトリウム 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 乳酸アルミニウム 1.0 1.0 1.0 5.0 1.0 1.0 3.0 2.0 モノフルオルリン酸 0.7 0.7 0.7 0.7 2.5 0.7 0.7 1.5 ナトリウム グリセリン 20 20 20 20 35 5 5 − ソルビトール 20 20 20 10 − 50 5 20 香料 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 水 残部 残部 残部 残部 残部 残部 残部 部残 pH 4.5 6.5 8.0 6.5 6.5 6.5 6.5 6.5 使用感 × ○ ○ × × × △ ○ 上記結果より、フッ素濃度が100〜2000ppmの範
囲内で、F:Al=1:0.3〜1:3であるときに、
はじめて著しい収れん感と金属味が抑えられ、使用感の
優れた組成物が得られることがわかった。[Table 3] Raw material name Compounding amount (%) ABCD FGH silica 20 20 20 20 20 20 20 20 Carboxymethyl 22 22 22 22 22 Sodium cellulose Sodium lauryl sulfate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 Sodium saccharin 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Aluminum lactate 1.0 1.0 1.0 5.0 1.0 1.0 3.0 2.0 Monofluorophosphoric acid 0.7 0.7 0.7 0.7 2.5 0.7 0.7 1.5 Sodium glycerin 20 20 20 20 35 5 5-Sorbitol 20 20 20 10-50 5 20 Fragrance 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Water Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining pH 4.5 6.5 8.0 6.5 6.5 6.5 6.5 6.5 Feeling × × ○ × × × × △ ○ From the above results, the fluorine concentration is 100 to 2000 ppm. When F: Al = 1: 0.3 to 1: 3,
For the first time, it was found that a remarkable astringent feeling and metallic taste were suppressed, and a composition excellent in use feeling was obtained.
【0017】次の実施例に具体的な組成物の組成を示
す。なお、「%」はいずれも重量%である。 実施例1 練歯磨 成分 配合量(%) シリカ 20.0 ソルビトール 30.0 グリセリン 8.0 カルボキシメチルセルロースナトリウム 1.6 サッカリンナトリウム 0.1 香料 1.0 乳酸アルミニウム 1.0 ラウリル硫酸ナトリウム 1.2 モノフルオロリン酸ナトリウム 0.7 水 100%に調整 (pH6.5に調整)The following examples show specific compositions of the compositions. In addition, all "%" are weight%. Example 1 Toothpaste Ingredient Content (%) Silica 20.0 Sorbitol 30.0 Glycerin 8.0 Sodium Carboxymethylcellulose 1.6 Sodium Saccharin 0.1 Fragrance 1.0 Aluminum Lactate 1.0 Sodium Lauryl Sulfate 1.2 Monofluoro Sodium phosphate 0.7 Water adjusted to 100% (pH adjusted to 6.5)
【0018】実施例2 マウスウォッシュ 成分 配合量(%) エチルアルコール 15.0 グリセリン 10.0 アスコルビン酸 0.03 乳酸アルミニウム 1.5 ポリオキシエチレン硬化ヒマシ油(60E.O.) 1.0 サッカリンナトリウム 0.05 フッ化ナトリウム 0.2 香料 0.3 水 100%に調整 (pH6.5に調整)Example 2 Mouthwash Ingredients Content (%) Ethyl alcohol 15.0 Glycerin 10.0 Ascorbic acid 0.03 Aluminum lactate 1.5 Polyoxyethylene hydrogenated castor oil (60 EO) 1.0 Saccharin sodium 0 .05 Sodium fluoride 0.2 Fragrance 0.3 Water adjusted to 100% (Adjusted to pH 6.5)
【0019】実施例3 練歯磨 成分 配合量(%) 第二リン酸カルシウム 40.0 ソルビトール 30.0 カルボキシメチルセルロースナトリウム 1.5 サッカリンナトリウム 0.1 香料 0.9 N−ラウロイルサルコシンナトリウム 0.5 ショ糖脂肪酸エステル 0.5 乳酸アルミニウム 2.0 フッ化ナトリウム 0.3 水 100%に調整 (pH8.0に調整)Example 3 Toothpaste Ingredients Amount (%) Dibasic calcium phosphate 40.0 Sorbitol 30.0 Sodium carboxymethylcellulose 1.5 Saccharin sodium 0.1 Fragrance 0.9 N-Lauroyl sarcosine sodium 0.5 Sucrose fatty acid ester 0.5 Aluminum lactate 2.0 Sodium fluoride 0.3 Water adjusted to 100% (Adjusted to pH 8.0)
【0020】実施例4 口腔用パスタ 成分 配合量(%) グリセリルモノステアレート 10.0 グリセリン 15.0 ヒドロキシエチルセルロース 5.0 セチルアルコール 3.0 ソルビタンモノオレート 5.0 香料 1.0 乳酸アルミニウム 1.5 モノフルオルリン酸ナトリウム 1.5 水 100%に調整 (pH5.5に調整)Example 4 Oral Pasta Ingredients Compounding Amount (%) Glyceryl Monostearate 10.0 Glycerin 15.0 Hydroxyethylcellulose 5.0 Cetyl Alcohol 3.0 Sorbitan Monooleate 5.0 Fragrance 1.0 Aluminum Lactate 1.0 5 Sodium monofluorophosphate 1.5 Adjusted to 100% water (Adjusted to pH 5.5)
【0021】[0021]
【発明の効果】本発明によれば、象牙質知覚過敏抑制効
果だけでなく、歯根面および象牙質う蝕抑制においても
優れた効果を有する口腔用組成物を得ることができる。According to the present invention, it is possible to obtain a composition for the oral cavity which has not only an effect of suppressing hypersensitivity to dentin but also an effect of suppressing dental root surfaces and dentin caries.
───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) A61K 7/18 ──────────────────────────────────────────────────続 き Continued on front page (58) Field surveyed (Int.Cl. 7 , DB name) A61K 7/18
Claims (1)
る口腔用組成物であって、フッ素濃度が100〜160
0ppmであり、フッ素とアルミニウムの配合比率がモル
比でF:Al=1:0.7〜1:2.8であり、pHが5
〜10であることを特徴とする口腔用組成物。1. An oral composition containing aluminum lactate and fluoride, wherein the fluorine concentration is 100 to 160.
0 ppm, the mixing ratio of fluorine and aluminum is F: Al = 1: 0.7-1: 2.8 in molar ratio, and the pH is 5
A composition for oral cavity, which is 10 to 10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32030591A JP3152467B2 (en) | 1991-12-04 | 1991-12-04 | Oral composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32030591A JP3152467B2 (en) | 1991-12-04 | 1991-12-04 | Oral composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05155745A JPH05155745A (en) | 1993-06-22 |
| JP3152467B2 true JP3152467B2 (en) | 2001-04-03 |
Family
ID=18120014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP32030591A Expired - Fee Related JP3152467B2 (en) | 1991-12-04 | 1991-12-04 | Oral composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3152467B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3877412B2 (en) * | 1996-12-16 | 2007-02-07 | アース製薬株式会社 | Liquid oral composition |
| JP2009256341A (en) * | 2008-03-27 | 2009-11-05 | Sunstar Inc | Dental caries preventive |
| JP5704637B2 (en) | 2009-12-16 | 2015-04-22 | 公益財団法人ヒューマンサイエンス振興財団 | Dental ultrasonic drug introduction system |
| JP5440150B2 (en) * | 2009-12-21 | 2014-03-12 | ライオン株式会社 | Oral composition |
| GB201811061D0 (en) * | 2018-07-05 | 2018-08-22 | GlaxoSmithKline Consumer Healthcare UK IP Ltd | Novel composition |
-
1991
- 1991-12-04 JP JP32030591A patent/JP3152467B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05155745A (en) | 1993-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4645662A (en) | Oral composition | |
| EP0278744B1 (en) | Dentifrice composition for desensitising sensitive teeth | |
| EP2306961A1 (en) | Composition and method for enhancing flouride uptake using bioactive glass | |
| KR101992927B1 (en) | Toothpaste composition for prevention and improvement of periodontal disease | |
| JP2017510618A (en) | How to protect and repair enamel | |
| JP2981772B2 (en) | Dental hygiene composition for reducing periodontal disease | |
| JPH09143043A (en) | Tartar softening / dissolving composition | |
| JPH1017449A (en) | Composition for hyperesthesia | |
| JP5720546B2 (en) | Dentifrice composition and tooth remineralization accelerator | |
| JP3152467B2 (en) | Oral composition | |
| JPH05155746A (en) | Composition for oral cavity | |
| JP3971881B2 (en) | Oral composition | |
| JP5709639B2 (en) | Oral composition | |
| EP0976380B1 (en) | Method of recalcifying teeth | |
| US5531983A (en) | Oral hygiene preparation | |
| Schaeken et al. | Control of calculus formation by a dentifrice containing calcium lactate | |
| JPH07165550A (en) | Oral composition | |
| KR100308247B1 (en) | Compositions for cleaning oral cavity | |
| JPH0629169B2 (en) | Oral composition | |
| Coessens et al. | Plaque-inhibiting effect of bioadhesive mucosal tablets containing chlorhexidine in a 4-day plaque regrowth model | |
| JP7073402B2 (en) | Oral composition | |
| US20260108434A1 (en) | Dentifrice comprising carboxylic acid or alkali metal salt thereof and a source of free fluoride ions | |
| JP2003160457A (en) | Preventive and therapeutic agent for dentin hypersensitivity | |
| WO2007065856A1 (en) | Oral compositions comprising rod-shaped apatite nanocrystals | |
| WO1992005765A1 (en) | Oral hygiene preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20000509 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20010109 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080126 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090126 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110126 Year of fee payment: 10 |
|
| LAPS | Cancellation because of no payment of annual fees |